Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/jcm11020441
Keywords
bronchiectasis; Germany; patient-reported outcome measures; quality of life; questionnaire design; registries
Categories
Funding
- Bayer Vital
- Grifols
- Insmed Inc.
- InfectoPharm
- German Ministry of Research and Education (BMBF) via the German Center for Lung Research (DZL)
- German Center for Infection Research (DZIF)
- European bronchiectasis registry EMBARC via the Innovative Medicines Initiative (IMI)
- European Commission
- iABC [115721]
Ask authors/readers for more resources
This study validates the German translation of the QOL-B version 3.1 by providing psychometric validation using baseline data, showing good validity and test-retest reliability. The QOL-B scale effectively assesses the quality of life of patients with bronchiectasis.
Patients with bronchiectasis feature considerable symptom burden and reduced health-related quality of life (QOL). We provide the psychometric validation of the German translation of the disease-specific Quality of Life Questionnaire-Bronchiectasis (QOL-B), version 3.1, using baseline data of adults consecutively enrolled into the prospective German bronchiectasis registry PROGNOSIS. Overall, 904 patients with evaluable QOL-B scores were included. We observed no relevant floor or ceiling effects. Internal consistency was good to excellent (Cronbach's alpha >= 0.73 for each scale). QOL-B scales discriminated between patients based on prior pulmonary exacerbations and hospitalizations, breathlessness, bronchiectasis severity index, lung function, sputum volume, Pseudomonas aeruginosa status and the need for regular pharmacotherapy, except for Social Functioning, Vitality and Emotional Functioning scales. We observed moderate to strong convergence between several measures of disease severity and QOL-B scales, except for Social and Emotional Functioning. Two-week test-retest reliability was good, with intraclass correlation coefficients >= 0.84 for each scale. Minimal clinical important difference ranged between 8.5 for the Respiratory Symptoms and 14.1 points for the Social Functioning scale. Overall, the German translation of the QOL-B, version 3.1, has good validity and test-retest reliability among a nationally representative adult bronchiectasis cohort. However, responsiveness of QOL-B scales require further investigation during registry follow-up.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available